Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0HGNSO)
| ADC Name |
ADRX-0405
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ADRX-0405
Click to Show/Hide
|
|||||
| Organization |
Adcentrx Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-STEAP1 antibody
|
Antibody Info | ||||
| Antigen Name |
Metalloreductase STEAP1 (STEAP1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key eligibility comprises Phase 1a patients with advanced mCRPC/GC/NSCLC and Phase 1b with castration-resistant prostate cancer (testosterone <50ng/dL) failing SOC therapies, requiring measurable disease (RECIST 1.1 or PCWG3) and ECOG 0-1/0-2 status. Major exclusions include active CNS metastases, significant CVD, recent malignancies (<3 years), current ILD/pneumonitis, or active infections (prophylaxis allowed).
Click to Show/Hide
|
||||
| Administration Dosage |
Increasing doses of ADRX-0405 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06710379 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary safety evaluation focuses on adverse event monitoring throughout the 2-year study period for ADRX-0405 in advanced solid tumors including mCRPC, GC, and NSCLC, particularly in treatment-resistant mCRPC cases.
|
||||
| Other Endpoint |
econdary assessments include comprehensive PK profiling (Ceoi/Cmax, Ctrough, AUC, t1/2, CL, Vss), immunogenicity (ADA incidence), and efficacy metrics (ORR by RECIST 1.1/PCWG3, DOR, DCR, PFS, rPFS, OS) all measured over the 2-year study duration.
|
||||